These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12419548)

  • 1. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
    Anker SD; Coats AJ
    Int J Cardiol; 2002 Dec; 86(2-3):123-30. PubMed ID: 12419548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.
    Coletta AP; Clark AL; Banarjee P; Cleland JG
    Eur J Heart Fail; 2002 Aug; 4(4):559-61. PubMed ID: 12167397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
    Mann DL; McMurray JJ; Packer M; Swedberg K; Borer JS; Colucci WS; Djian J; Drexler H; Feldman A; Kober L; Krum H; Liu P; Nieminen M; Tavazzi L; van Veldhuisen DJ; Waldenstrom A; Warren M; Westheim A; Zannad F; Fleming T
    Circulation; 2004 Apr; 109(13):1594-602. PubMed ID: 15023878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Hanauer SB; Katz S; Safdi M; Wolf DG; Baerg RD; Tremaine WJ; Johnson T; Diehl NN; Zinsmeister AR
    Gastroenterology; 2001 Nov; 121(5):1088-94. PubMed ID: 11677200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
    Chung ES; Packer M; Lo KH; Fasanmade AA; Willerson JT;
    Circulation; 2003 Jul; 107(25):3133-40. PubMed ID: 12796126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA; Symmons DP; Noyce PR; Ashcroft DM
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.
    Bozkurt B; Torre-Amione G; Warren MS; Whitmore J; Soran OZ; Feldman AM; Mann DL
    Circulation; 2001 Feb; 103(8):1044-7. PubMed ID: 11222463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept: a review of its use in rheumatoid arthritis.
    Jarvis B; Faulds D
    Drugs; 1999 Jun; 57(6):945-66. PubMed ID: 10400407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokines--causes, players or bystanders in heart failure].
    Staudt A; Landsberger M; Staudt Y; Felix SB
    Herz; 2002 Nov; 27(7):691-8. PubMed ID: 12439641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of TNF blocking therapy in heart failure.
    Gupta S; Tripathi CD
    Indian J Med Sci; 2005 Aug; 59(8):363-6. PubMed ID: 16129932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.